{"id":21118,"date":"2021-02-16T15:13:00","date_gmt":"2021-02-16T15:13:00","guid":{"rendered":"https:\/\/celonpharma.com\/?p=21118"},"modified":"2021-05-31T15:16:23","modified_gmt":"2021-05-31T15:16:23","slug":"current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/","title":{"rendered":"Current report No. 11\/2021 \u2013 List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of the Company held on 16 February 2021"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">February 16, 2021<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Legal basis subs. 70 point 3 of the Act on Public Offering \u2013 General Shareholder&#8217;s Meeting, the above 5% list<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Content of the report:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Acting pursuant to Article 70 point 3 of the Act on Public Offering [&#8230;] Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby informs that the shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company held on 16 February 2021 were:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8211; Glatton sp. z o.o., holder of 30,003,531 shares in the Company, representing 45,003,531 votes, which constituted 75.01% of the total number of votes in the Company and 89.62% of votes at this Extraordinary General Meeting, &#8211; Generali Otwarty Fundusz Emerytalny, holder of 3,000,000 shares in the Company, representing 3,000,000 votes, which constituted 5.00% of the total number of votes in the Company and 5.97% of votes at this Extraordinary General Meeting<\/p>\n","protected":false},"excerpt":{"rendered":"<p>February 16, 2021 Legal basis subs. 70 point 3 of the Act on Public Offering \u2013 General Shareholder&#8217;s Meeting, the above 5% list Content of the report: Acting pursuant to Article 70 point 3 of the Act on Public Offering [&#8230;] Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby informs that the shareholders holding<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/\" title=\"ReadCurrent report No. 11\/2021 \u2013 List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of the Company held on 16 February 2021\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":20,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[46],"tags":[],"class_list":["post-21118","post","type-post","status-publish","format-standard","hentry","category-current-reports"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Current report No. 11\/2021 \u2013 List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of the Company held on 16 February 2021 - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current report No. 11\/2021 \u2013 List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of the Company held on 16 February 2021 - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"February 16, 2021 Legal basis subs. 70 point 3 of the Act on Public Offering \u2013 General Shareholder&#8217;s Meeting, the above 5% list Content of the report: Acting pursuant to Article 70 point 3 of the Act on Public Offering [&#8230;] Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby informs that the shareholders holdingRead more &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-16T15:13:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-31T15:16:23+00:00\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\\\/\"},\"author\":{\"name\":\"Ma\u0142gorzata Siewierska\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"headline\":\"Current report No. 11\\\/2021 \u2013 List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of the Company held on 16 February 2021\",\"datePublished\":\"2021-02-16T15:13:00+00:00\",\"dateModified\":\"2021-05-31T15:16:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\\\/\"},\"wordCount\":152,\"articleSection\":[\"Current reports\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\\\/\",\"name\":\"Current report No. 11\\\/2021 \u2013 List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of the Company held on 16 February 2021 - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2021-02-16T15:13:00+00:00\",\"dateModified\":\"2021-05-31T15:16:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Current report No. 11\\\/2021 \u2013 List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of the Company held on 16 February 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\",\"name\":\"Ma\u0142gorzata Siewierska\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current report No. 11\/2021 \u2013 List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of the Company held on 16 February 2021 - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/","og_locale":"en_US","og_type":"article","og_title":"Current report No. 11\/2021 \u2013 List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of the Company held on 16 February 2021 - Celon Pharma","og_description":"February 16, 2021 Legal basis subs. 70 point 3 of the Act on Public Offering \u2013 General Shareholder&#8217;s Meeting, the above 5% list Content of the report: Acting pursuant to Article 70 point 3 of the Act on Public Offering [&#8230;] Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby informs that the shareholders holdingRead more &raquo;","og_url":"https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/","og_site_name":"Celon Pharma","article_published_time":"2021-02-16T15:13:00+00:00","article_modified_time":"2021-05-31T15:16:23+00:00","author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/"},"author":{"name":"Ma\u0142gorzata Siewierska","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"headline":"Current report No. 11\/2021 \u2013 List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of the Company held on 16 February 2021","datePublished":"2021-02-16T15:13:00+00:00","dateModified":"2021-05-31T15:16:23+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/"},"wordCount":152,"articleSection":["Current reports"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/","url":"https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/","name":"Current report No. 11\/2021 \u2013 List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of the Company held on 16 February 2021 - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2021-02-16T15:13:00+00:00","dateModified":"2021-05-31T15:16:23+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/current-report-no-11-2021-list-of-shareholders-holding-at-least-5-of-the-votes-at-the-extraordinary-general-meeting-of-the-company-held-on-16-february-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Current report No. 11\/2021 \u2013 List of shareholders holding at least 5% of the votes at the Extraordinary General Meeting of the Company held on 16 February 2021"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c","name":"Ma\u0142gorzata Siewierska"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/21118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=21118"}],"version-history":[{"count":2,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/21118\/revisions"}],"predecessor-version":[{"id":21120,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/21118\/revisions\/21120"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=21118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=21118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=21118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}